Research Topics
| Danial E BakerSummaryAffiliation: Washington State University Country: USA Publications
|
Detail Information
Publications
Certolizumab pegol for the treatment of Crohn's diseaseDanial E Baker
Director, Drug Information Center Professor of Pharmacotherapy, College of Pharmacy, Washington State University Spokane, PO Box 1495, Spokane, WA 99210 1495, USA
Expert Rev Clin Immunol 5:683-91. 2009..Concomitant use with anakinra is not recommended because of the increased risk of serious infections and neutropenia. Therapy should be discontinued if the patient develops a serious infection during therapy...- Rationale for using serotonergic agents to treat irritable bowel syndromeDanial E Baker
College of Pharmacy, Washington State University, P O Box 1495, Spokane, WA 99210 1495, USA
Am J Health Syst Pharm 62:700-11; quiz 712-3. 2005.... - Inhaled dry powder insulin for the treatment of diabetes mellitusStephen M Setter
Department of Pharmacotherapy, College o f Pharmacy, Washington State University, Spokane, WA 99217 6131, USA
Clin Ther 29:795-813. 2007..Inhaled dry powder insulin (IDPI) is the first inhaled insulin approved for the treatment of type 1 and type 2 diabetes mellitus (DM)... - Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitusJason L Iltz
Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, 99210 1495, USA
Clin Ther 28:652-65. 2006.... - Insulin glargine: a new basal insulinTerri L Levien
College of Pharmacy, Washington State University Spokane, 99202 1675, USA
Ann Pharmacother 36:1019-27. 2002..To review the pharmacology, pharmacokinetics, dosing guidelines, adverse effects, drug interactions, and clinical efficacy of insulin glargine... - The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitisDanial E Baker
College of Pharmacy, Washington State University, Spokane, WA, USA
Rev Gastroenterol Disord 4:86-91. 2004..If patients are unable to tolerate any one of these three 5-aminosalicylic acid-releasing preparations, they might be able to tolerate one of the others, as long as the intolerance is not due to hypersensitivity to 5-aminosalicylic acid... - Phosphodiesterase 5 inhibitors for erectile dysfunctionStephen M Setter
Department of Pharmacotherapy, College of Pharmacy, Washington State University Elder Services, Spokane, WA 99217 6131, USA
Ann Pharmacother 39:1286-95. 2005..To review the pharmacologic and clinical trial data of the Food and Drug Administration-approved phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile dysfunction (ED)... - Natalizumab: overview of its pharmacology and safetyDanial E Baker
College of Pharmacy, Washington State University Spokane, Spokane, Washington, USA
Rev Gastroenterol Disord 7:38-46. 2007..This program requires all patients prescribed natalizumab to be enrolled in and to receive their medication through the TOUCH system. Any serious adverse reactions must be reported to the TOUCH and MedWatch systems... - Pharmacogenomics of azathioprine and 6-mercaptopurine in gastroenterologic therapyDanial E Baker
College of Pharmacy, Washington State University, Spokane, Washington, USA
Rev Gastroenterol Disord 3:150-7. 2003..However, measuring the TPMT activity at baseline is not a substitute for monitoring white blood cell counts throughout therapy because drug therapy and/or other conditions may still cause myelosuppression in these patients... - Peptic ulcer bleeding following therapeutic endoscopy: a new indication for intravenous esomeprazoleDanial E Baker
Drug Information Center, Department of Pharmacotherapy, Washington State University, Spokane, USA
Rev Gastroenterol Disord 9:E111-8. 2009..What remains to be seen is whether oral therapy can be substituted for all, or part, of the 72-hour IV infusion and whether the patient can be discharged from the hospital sooner with similar outcomes... - Methylnaltrexone bromide: new drug for the treatment of opioid-induced bowel dysfunctionDanial E Baker
Drug Information Center, Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, WA, USA
Rev Gastroenterol Disord 9:E84-93. 2009..Methylnaltrexone appears effective in the therapy of opioid-induced constipation and will be useful for patients failing to respond to traditional laxative regimens... - Imatinib mesylateDanial E Baker
College of Pharmacy, Washington State University, Spokane, WA, USA
Rev Gastroenterol Disord 2:75-86. 2002.... - Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicityDanial E Baker
College of Pharmacy, Washington State University, Spokane, WA, USA
Rev Gastroenterol Disord 2:20-33. 2002..g., avoid lying down for 30 minutes after taking the drug and take the drug with a full glass of water) and may be decreased with once-weekly dosing... - Intravenous proton pump inhibitorsDanial E Baker
College of Pharmacy, Washington State University, Spokane, Washington, USA
Rev Gastroenterol Disord 6:22-34. 2006.... - Safety of balsalazide therapy in the treatment of inflammatory bowel diseaseDanial E Baker
College of Pharmacy, Washington State University, Spokane, Washington, USA
Rev Gastroenterol Disord 5:135-41. 2005..Overall, balsalazide is well tolerated and effective in the treatment of IBD... - Esomeprazole: update and clinical reviewDanial E Baker
College of Pharmacy, Washington State University, Spokane, Washington, USA
Rev Gastroenterol Disord 2:189-99. 2002..The results of these studies indicate that all the proton pump inhibitors are effective in treating GERD and erosive esophagitis and that some patients would benefit from esomeprazole therapy... - Pegylated interferon plus ribavirin for the treatment of chronic hepatitis CDanial E Baker
College of Pharmacy, Washington State University, Spokane, WA, USA
Rev Gastroenterol Disord 3:93-109. 2003..Studies directly comparing peginterferon alfa-2a and peginterferon alfa-2b have not been performed... - Adefovir dipivoxil: focus on its use in the treatment of chronic hepatitis BDanial E Baker
College of Pharmacy, Washington State University, Spokane, Washington, USA
Rev Gastroenterol Disord 5:89-100. 2005..Lactic acidosis and severe hepatomegaly with steatosis may also occur during therapy...